Edward Nash

Q: How accurate are Edward Nash's stock ratings?

About 42% of Edward's ratings were profitable over a one-year hold, with an average return of +2.4% per rating, measured by 13Foresight from historical prices.

Q: How is Edward ranked?

Edward Nash is ranked #2298 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Canaccord Genuity

Wall Street Analyst

★★☆☆☆

#2298

on 13Foresight · ranked by our own returns

40%

Success Rate

+2.1%

Average Return

38 of 95 calls profitable · -0.7% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 40% of Edward Nash's ratings turned a profit when each position was held for 1 year — averaging +2.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

132 Buy 7 Hold 0 Sell

Edward's Stock Coverage 42 ratings · 2026-11-05

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
VKTX Viking Therapeutics	Oct 30, 2026	BUY	Strong Buy +172.0% avg upside 31 analysts	$118.00 332.50% Upside	-1.7%	·
KYMR Kymera Therapeutics	Oct 30, 2026	BUY	Strong Buy -9.7% avg upside 39 analysts	$129.00 1.80% Upside	+0.5%	·
ACRS Aclaris Therapeutics	Oct 30, 2026	BUY	Strong Buy +155.5% avg upside 16 analysts	$13.00 227.51% Upside	-9.1%	·
MDGL Madrigal Pharmaceuticals	Oct 29, 2026	BUY	Strong Buy +20.2% avg upside 34 analysts	$612.00 42.24% Upside	-6.0%	·
TVTX Travere Therapeutics	Oct 28, 2026	BUY	Strong Buy +15.5% avg upside 22 analysts	$70.00 38.93% Upside	-3.9%	·
TSE:CRDL Cardiol Therapeutics	Oct 28, 2026	BUY	Strong Buy +637.3% avg upside 7 analysts	$13.97 762.64% Upside	-3.6%	·
KNSA Kiniksa Pharmaceuticals	Oct 28, 2026	BUY	Strong Buy -11.0% avg upside 12 analysts	$98.00 6.18% Upside	-7.2%	·
CORT Corcept Therapeutics	Oct 27, 2026	BUY	Buy -17.9% avg upside 16 analysts	$161.00 98.42% Upside	-18.2%	·
TRAX First Tracks Biotherapeutics Inc	Oct 13, 2026	BUY	Strong Buy +64.6% avg upside 11 analysts	$60.00 33.07% Upside	+54.8%	·
CNTB Connect Biopharma Holdings	Oct 01, 2026	BUY	Strong Buy +718.8% avg upside 12 analysts	$6.00 648.04% Upside	-18.2%	·
SGMT Sagimet Biosciences, Inc. Class A	Oct 01, 2026	BUY	Strong Buy +194.3% avg upside 17 analysts	$56.00 464.61% Upside	+11.3%	·
IVA Inventiva	Sep 29, 2026	BUY	Strong Buy +350.4% avg upside 17 analysts	$21.00 475.37% Upside	+16.4%	·
NKTR Nektar Therapeutics	Sep 28, 2026	BUY	Strong Buy +97.0% avg upside 26 analysts	$153.00 293.66% Upside	-36.3%	·
CLDX Celldex	Sep 23, 2026	BUY	Strong Buy +42.9% avg upside 28 analysts	$60.00 99.27% Upside	-9.2%	·
GPCR Structure Therapeutics, Inc. Sponsored ADR	Sep 09, 2026	BUY	Strong Buy +373.2% avg upside 17 analysts	$111.00 407.51% Upside	-50.3%	·
RANI Rani Therapeutics Holdings	Aug 17, 2026	BUY	Strong Buy +1444.2% avg upside 10 analysts	$5.00 747.51% Upside	-25.9%	·
PLRX Pliant Therapeutics	Aug 13, 2026	HOLD	Buy +2494.5% avg upside 21 analysts	$3.00 249.25% Upside	-22.3%	·
VERU Veru	May 14, 2026	BUY	Strong Buy +838.4% avg upside 11 analysts	$25.00 1041.46% Upside	+4.8%	·
RZLT Rezolute	Oct 02, 2024	BUY	Strong Buy +197.5% avg upside 14 analysts	$9.00 127.80% Upside	+95.1%	·
ORMP Oramed Pharm	May 17, 2023	HOLD	Strong Buy +367.2% avg upside 7 analysts	$2.00 51.39% Downside	-36.6%	·
EOCN Eocene	Aug 08, 2022	HOLD	Buy +688.3% avg upside 13 analysts	$15.00 383.96% Upside	·	·
OBSEF ObsEva	Jul 29, 2022	HOLD	Buy +10799900.0% avg upside 8 analysts	$1.00 999899.93% Upside	·	·
XGN Exagen	May 18, 2021	BUY	Strong Buy +50.2% avg upside 11 analysts	$25.00 190.97% Upside	-68.0%	·
IFRX InflaRx	Jun 05, 2019	HOLD	Buy +430.1% avg upside 12 analysts	$5.00 201.11% Upside	+144.8%	·
WVE Wave Life Sciences	May 20, 2019	BUY	Strong Buy +443.6% avg upside 30 analysts	$39.00 986.36% Upside	-55.2%	·
SRPT Sarepta Therapeutics	Feb 27, 2019	BUY	Buy +223.8% avg upside 50 analysts	$176.00 845.15% Upside	-29.0%	·
QURE uniQure	Feb 26, 2019	BUY	Strong Buy +121.1% avg upside 30 analysts	$64.00 157.73% Upside	+0.0%	·
BMRN BioMarin Pharmaceutical	Feb 25, 2019	BUY	Strong Buy +63.6% avg upside 52 analysts	$117.00 99.98% Upside	-0.4%	·
RARE Ultragenyx Pharmaceutical	Jan 23, 2019	BUY	Strong Buy +193.8% avg upside 36 analysts	$71.00 341.04% Upside	+16.2%	·
ANAB AnaptysBio	Sep 24, 2018	BUY	Strong Buy +48.7% avg upside 26 analysts	$156.00 223.04% Upside	-62.3%	·
ARGX Argenx Se	Sep 17, 2018	BUY	Strong Buy -8.2% avg upside 48 analysts	$132.00 85.28% Downside	+37.5%	·
SMMT Summit Therapeutics	Jun 27, 2018	HOLD	Strong Buy +83.4% avg upside 29 analysts	$4.00 75.11% Downside	-48.6%	·
ELOX Eloxx Pharmaceuticals	Jun 25, 2018	BUY	Strong Buy +168.9% avg upside 13 analysts	$26.00 93.34% Upside	·	·
ABEO Abeona Therapeutics	May 16, 2018	BUY	Strong Buy +295.1% avg upside 18 analysts	$23.00 428.73% Upside	·	·
NBRVF Nabriva Therapeutics	Sep 18, 2017	BUY	Buy +13374900.0% avg upside 9 analysts	$24.00 23999900.05% Upside	·	·
ANTH Anthera Pharmaceuticals	May 16, 2017	HOLD	Buy +4728471.4% avg upside 9 analysts	$2.00 1999900.01% Upside	·	·
LRMR Larimar Therapeutics	May 05, 2017	HOLD	Strong Buy +621.1% avg upside 22 analysts	$6.00 142.82% Upside	·	·
IMUX Immunic	Mar 07, 2017	HOLD	Strong Buy +399.8% avg upside 23 analysts	$9.00 19.91% Upside	·	·
IRWD Ironwood Pharma	Sep 04, 2014	HOLD	Buy +239.4% avg upside 23 analysts	$10.50 199.99% Upside	-10.8%	·
SGMOQ Sangamo Therapeutics	Jun 17, 2013	BUY	Buy +9563.8% avg upside 16 analysts	—	·	·
DCTH Delcath Systems	May 03, 2013	SELL	Strong Buy +55.2% avg upside 12 analysts	—	·	·
ACAD ACADIA Pharmaceuticals	Jan 28, 2013	BUY	Strong Buy +71.5% avg upside 43 analysts	—	+255.3%	·

🔒 37 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Edward Nash — Frequently Asked Questions

How accurate are Edward Nash's stock ratings?

Based on the calls 13Foresight could measure, about 42% of Edward's ratings were profitable over a one-year hold, with an average return of +2.4% per rating, or -0.4% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Edward ranked on 13Foresight?

Edward Nash is currently ranked #2298 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Edward cover?

Edward most recently has ratings on VKTX, KYMR, ACRS, MDGL, TVTX, TSE:CRDL, KNSA, CORT, TRAX, CNTB, SGMT, IVA and 30 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Edward Nash

Rating Distribution

Welcome to 13Foresight!